Researchers from Revolo Biotherapeutics Ltd. recently presented preclinical data for IRL-201104, a clinical-stage immunomodulatory peptide currently in phase II development as an intravenous treatment ...
NEW YORK--(BUSINESS WIRE)--Neurogene Inc., a company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced results of a well ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback